Shaitelman SF, et al. - Because of concerns about its safety when used with a tumor bed boost or in patients who have received chemotherapy or have large breast size, adoption of hypofractionated whole-breast irradiation (HF-WBI) remains low, so experts compared conventionally fractionated whole-breast irradiation (CF-WBI; 50 Gy/25 fx + 10 to 14 Gy/5 to 7 fx) with HF-WBI (42.56 Gy/16 fx + 10 to 12.5 Gy/4 to 5 fx). Forthis study, 287 women with stage 0 to II breast cancer were randomly assigned to CF-WBI or HF-WBI, stratified by chemotherapy, margin status, cosmesis, and breast size from 2011 to 2014. They noted comparable outcomes with hypofractionation and conventional fractionation 3 years after WBI followed by a tumor bed boost. For HF-WBI, tumor bed boost, chemotherapy, and larger breast size were not strong contraindications.